Jounce Therapeutics, Inc. (NASDAQ:JNCE – Get Rating) has been given an average rating of “Buy” by the eight analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average […]
Wall Street analysts predict that Jounce Therapeutics, Inc. (NASDAQ:JNCE – Get Rating) will report earnings per share (EPS) of ($0.57) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Jounce Therapeutics’ earnings. The highest EPS estimate is ($0.46) and the lowest is ($0.62). Jounce Therapeutics posted earnings of ($0.58) per share […]
Jounce Therapeutics, Inc. (NASDAQ:JNCE – Get Rating) – Research analysts at Piper Sandler cut their FY2022 earnings per share estimates for Jounce Therapeutics in a research note issued on Wednesday, March 2nd. Piper Sandler analyst E. Tenthoff now anticipates that the company will earn ($2.63) per share for the year, down from their prior estimate […]